SoylentNews is people
SoylentNews
Submitted via IRC for chromas
The West Virginia University Rockefeller Neuroscience Institute and WVU Medicine, today (Nov. 5) announced the launch of a first-in-the-U.S. clinical trial using deep brain stimulation for patients suffering from treatment-resistant opioid use disorder.
Funded through a grant from the National Institute on Drug Abuse, the clinical trial is led by principal investigator Ali Rezai, M.D., executive chair of the RNI, and a multidisciplinary team of neurosurgical, psychiatric, neuroscience, and other experts.
The team successfully implanted a Medtronic DBS device in the addiction and reward center of the brain. The trial's first participant is a 33-year-old man, who has struggled with substance use disorder, specifically excessive opioid and benzodiazepine use, for more than a decade with multiple overdoses and relapses.
[...] "Our team at the RNI is working hard to find solutions to help those affected by addiction," Dr. Rezai said. "Addiction is a brain disease involving the reward centers in the brain, and we need to explore new technologies, such as the use of DBS, to help those severely impacted by opioid use disorder."
Also at TechCrunch and Engadget.
(Score: 5, Insightful) by c0lo on Wednesday November 06 2019, @01:46AM (1 child)
For a being posing as superior in intellect to hoomans, you show yourself quite obtuse.
You don't seem to get that the epidemic wasn't a bug in the first place... for the suppliers and their profits... it was a feature.
So, forget the hoomans, they have nothing to say about what is a problem and what is not, its the "corporate people" that know better.
And the actual problem is the corporate suppliers of hooman-adjustment-chemicals can't keep their exclusivity on the market for long. And the same will happen with DMT or shrooms.
On the other side, personalized holes in the brain?... I dare you switch the suppliers after they'll be implanting the "genuine inkjet protection"-like chip in your brain.
https://www.youtube.com/watch?v=aoFiw2jMy-0 https://soylentnews.org/~MichaelDavidCrawford
(Score: 2, Informative) by Anonymous Coward on Wednesday November 06 2019, @03:53AM
Your analysis is correct, including the wet dream of a Skynet Trusted Platform Module to add to hooman brains. I'm anxious to see how capital screws up the legal weed.
My guess is they'll do it with early harvesting. I've gotten some bud from gray market, and looking at the trichromes under microscope, it seemed the buds were barely ready to harvest. Experience from those buds was not as good as artisan, non-GMO, organic, grown in small batches, etc. I tried several different strains (no idea what they were exactly), and they were all missing something. My wild guess, without sending samples off to labs, is that the answer will be CBN.
If on the early side of the harvest window, then buds end up with too much THC compared to other chemicals like CBN (am thinking ratio is important here), which can lead to paranoia and overall bad experiences. But capital will harvest early because product must movemovemove! When growing, I recommend waiting a while (not too long, just a couple weeks, ymmv, don't rely on trichromes alone) for CBN to accumulate and THC to moderate a bit, since CBN helps with sleep and anxiety--makes an overall better and more uplifting experience instead of just a different color of drunk that instead interferes with sleep, if that makes sense.
Of course, if looking for palliative care for pain (as in opioid alternative for chronic pain management) and the rest the non-psychological medicinal properties, then CBD is the winner, but that's dependent on strain instead of harvest timing.